Tasly Pharmaceutical Group Co Ltd Cash Flow Conversion Efficiency

Latest as of December 2025: 0.044x

Tasly Pharmaceutical Group Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Tasly Pharmaceutical Group Co Ltd (600535) has a cash flow conversion efficiency ratio of 0.044x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥552.13 Million ≈ $80.79 Million USD) by net assets (CN¥12.55 Billion ≈ $1.84 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Tasly Pharmaceutical Group Co Ltd (2001–2025)

Cash flow conversion efficiency of Tasly Pharmaceutical Group Co Ltd from 2001 to 2025. This chart illustrates how Tasly Pharmaceutical Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 600535 stock price for real-time trading data and today's change.

Tasly Pharmaceutical Group Co Ltd Cash Flow Conversion Ratio Explained

Tasly Pharmaceutical Group Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Tasly Pharmaceutical Group Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tasly Pharmaceutical Group Co Ltd ranked by their cash flow conversion efficiency. Also see 600535 company net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
New Hope Corporation Ltd AU:NHC	0.071x
GEPIC Energy Development Co Ltd SHE:000791	0.108x
Group 1 Automotive Inc NYSE:GPI	0.046x
Fujian Sunner Development Co Ltd SHE:002299	0.143x
Graphic Packaging Holding Company NYSE:GPK	-0.035x
Xi an Bright Laser Tech Co Ltd SHG:688333	0.022x
SunocoCorp LLC NYSE:SUNC	0.003x
Adaro Minerals Indonesia Tbk PT JK:ADMR	0.074x

Annual Cash Flow Conversion Efficiency for Tasly Pharmaceutical Group Co Ltd (2001–2025)

The table below shows the annual cash flow conversion efficiency of Tasly Pharmaceutical Group Co Ltd from 2001 to 2025. Review Tasly Pharmaceutical Group Co Ltd (600535) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥12.55 Billion ≈ $1.84 Billion	CN¥1.42 Billion ≈ $208.49 Million	0.114x	-31.74%
2024-12-31	CN¥12.11 Billion ≈ $1.77 Billion	CN¥2.01 Billion ≈ $294.79 Million	0.166x	-18.05%
2023-12-31	CN¥12.69 Billion ≈ $1.86 Billion	CN¥2.58 Billion ≈ $376.90 Million	0.203x	+12.19%
2022-12-31	CN¥12.63 Billion ≈ $1.85 Billion	CN¥2.29 Billion ≈ $334.39 Million	0.181x	-14.01%
2021-12-31	CN¥13.31 Billion ≈ $1.95 Billion	CN¥2.80 Billion ≈ $409.90 Million	0.210x	+45.47%
2020-12-31	CN¥12.38 Billion ≈ $1.81 Billion	CN¥1.79 Billion ≈ $262.10 Million	0.145x	+2.12%
2019-12-31	CN¥11.86 Billion ≈ $1.74 Billion	CN¥1.68 Billion ≈ $245.86 Million	0.142x	+6.27%
2018-12-31	CN¥11.21 Billion ≈ $1.64 Billion	CN¥1.49 Billion ≈ $218.59 Million	0.133x	+245.41%
2017-12-31	CN¥8.97 Billion ≈ $1.31 Billion	CN¥-822.56 Million ≈ $-120.37 Million	-0.092x	-165.20%
2016-12-31	CN¥8.21 Billion ≈ $1.20 Billion	CN¥1.15 Billion ≈ $168.83 Million	0.141x	+218.67%
2015-12-31	CN¥7.71 Billion ≈ $1.13 Billion	CN¥340.00 Million ≈ $49.75 Million	0.044x	-63.75%
2014-12-31	CN¥5.07 Billion ≈ $741.67 Million	CN¥616.76 Million ≈ $90.25 Million	0.122x	+45.65%
2013-12-31	CN¥4.14 Billion ≈ $606.32 Million	CN¥346.17 Million ≈ $50.66 Million	0.084x	-14.97%
2012-12-31	CN¥4.21 Billion ≈ $615.55 Million	CN¥413.31 Million ≈ $60.48 Million	0.098x	+174.55%
2011-12-31	CN¥3.78 Billion ≈ $552.55 Million	CN¥135.14 Million ≈ $19.77 Million	0.036x	-68.97%
2010-12-31	CN¥3.42 Billion ≈ $501.18 Million	CN¥395.05 Million ≈ $57.81 Million	0.115x	-37.45%
2009-12-31	CN¥2.17 Billion ≈ $317.70 Million	CN¥400.39 Million ≈ $58.59 Million	0.184x	+48.33%
2008-12-31	CN¥2.09 Billion ≈ $306.26 Million	CN¥260.21 Million ≈ $38.08 Million	0.124x	+10.81%
2007-12-31	CN¥1.97 Billion ≈ $288.96 Million	CN¥221.55 Million ≈ $32.42 Million	0.112x	+37.29%
2006-12-31	CN¥1.72 Billion ≈ $251.70 Million	CN¥140.56 Million ≈ $20.57 Million	0.082x	-40.49%
2005-12-31	CN¥1.56 Billion ≈ $229.00 Million	CN¥214.90 Million ≈ $31.45 Million	0.137x	-7.13%
2004-12-31	CN¥1.37 Billion ≈ $201.15 Million	CN¥203.27 Million ≈ $29.74 Million	0.148x	+201.11%
2003-12-31	CN¥1.20 Billion ≈ $175.82 Million	CN¥59.00 Million ≈ $8.63 Million	0.049x	-76.26%
2002-12-31	CN¥997.00 Million ≈ $145.89 Million	CN¥206.22 Million ≈ $30.18 Million	0.207x	-38.96%
2001-12-31	CN¥247.20 Million ≈ $36.17 Million	CN¥83.77 Million ≈ $12.26 Million	0.339x	--

About Tasly Pharmaceutical Group Co Ltd

SHG:600535 China Drug Manufacturers - Specialty & Generic

Market Cap

$3.15 Billion

CN¥21.50 Billion CNY

Market Cap Rank

#4619 Global

#712 in China

Share Price

CN¥14.39

Change (1 day)

-0.35%

52-Week Range

CN¥13.23 - CN¥16.12

All Time High

CN¥29.37